- Home
- NCNA vs GTBP Comparison
NCNA vs GTBP Comparison
Compare NCNA & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | GTBP |
|---|---|---|
| Founded | 1997 | 1965 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 8.8M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NCNA | GTBP |
|---|---|---|
| Price | $2.00 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 38.0K | ★ 2.2M |
| Earning Date | 06-01-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.26 |
| 52 Week High | $10.00 | $3.73 |
Technical Indicators
Market Signals| Indicator | NCNA | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 52.83 |
| Support Level | $1.83 | $0.39 |
| Resistance Level | $2.28 | $0.46 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.49 | 57.60 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.